Charles F Yates1,2,3, Kate Riney4,5, Stephen Malone4,5, Ubaid Shah4,5, Liam G Coulthard6,7,4, Robert Campbell6,4, Geoff Wallace5, Martin Wood6. 1. Department of Neurosurgery, Queensland Children's Hospital, Brisbane, QLD, Australia. Charles.Yates@health.qld.gov.au. 2. Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. Charles.Yates@health.qld.gov.au. 3. School of Medicine, University of Queensland, Brisbane, QLD, Australia. Charles.Yates@health.qld.gov.au. 4. School of Medicine, University of Queensland, Brisbane, QLD, Australia. 5. Neurosciences Unit, Queensland Children's Hospital, Brisbane, QLD, Australia. 6. Department of Neurosurgery, Queensland Children's Hospital, Brisbane, QLD, Australia. 7. Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Abstract
BACKGROUND: Vagus nerve stimulation (VNS) therapy was first approved in the mid-1990s in the USA, Europe and Australia, with demonstrable efficacy in paediatric populations. Benefit in seizure frequency reduction can be observed up to 2 years post-intervention; however, few studies assess outcomes beyond this period. Furthermore, paediatric cohort sizes are small, limiting generalisability of outcome assessments. We evaluate VNS insertion outcomes and complications or side-effects in a large paediatric cohort, over a 20-year period from Queensland's first VNS insertion. METHODS: A retrospective review was conducted of all paediatric VNS insertions at the Queensland Children's Hospital (QCH) and the Mater Children's Hospital/Mater Children's Private Hospital (MCH/MCPH) Brisbane. A minimum of 1-year follow-up from 1999 to 2020 was required for inclusion. Patients were assessed on demographics, epilepsy details, seizure outcomes and complications or side-effects. RESULTS: In this extended follow-up cohort (76 patients, 7.2 ± 5.3 years), 51.3% of patients had ≥ 50% seizure frequency reduction, while 73.7% experienced an Engel III outcome (worthwhile benefit) or better. Eleven patients (14.9%) were seizure-free at follow-up, and 81.6% retained long-term therapy. Stimulation-related side-effects are common (17.1%) but rarely result in stimulation cessation (3.9%). Cessation occurred in 14 patients (18.4%) and most commonly related to minimal benefit (13.2%). Demographics, aetiology, seizure nature and surgical factors did not influence outcomes. CONCLUSION: Over extended treatment periods, a large proportion of patients will benefit significantly from VNS therapy. Approximately 4 of 5 patients will retain VNS therapy, and in cases of cessation, this is most commonly related to minimal benefit. Underlying demographics, aetiology or seizure nature do not influence outcomes. This 20-year Queensland assessment of VNS therapy outcomes informs long-term expectation of VNS therapy.
BACKGROUND: Vagus nerve stimulation (VNS) therapy was first approved in the mid-1990s in the USA, Europe and Australia, with demonstrable efficacy in paediatric populations. Benefit in seizure frequency reduction can be observed up to 2 years post-intervention; however, few studies assess outcomes beyond this period. Furthermore, paediatric cohort sizes are small, limiting generalisability of outcome assessments. We evaluate VNS insertion outcomes and complications or side-effects in a large paediatric cohort, over a 20-year period from Queensland's first VNS insertion. METHODS: A retrospective review was conducted of all paediatric VNS insertions at the Queensland Children's Hospital (QCH) and the Mater Children's Hospital/Mater Children's Private Hospital (MCH/MCPH) Brisbane. A minimum of 1-year follow-up from 1999 to 2020 was required for inclusion. Patients were assessed on demographics, epilepsy details, seizure outcomes and complications or side-effects. RESULTS: In this extended follow-up cohort (76 patients, 7.2 ± 5.3 years), 51.3% of patients had ≥ 50% seizure frequency reduction, while 73.7% experienced an Engel III outcome (worthwhile benefit) or better. Eleven patients (14.9%) were seizure-free at follow-up, and 81.6% retained long-term therapy. Stimulation-related side-effects are common (17.1%) but rarely result in stimulation cessation (3.9%). Cessation occurred in 14 patients (18.4%) and most commonly related to minimal benefit (13.2%). Demographics, aetiology, seizure nature and surgical factors did not influence outcomes. CONCLUSION: Over extended treatment periods, a large proportion of patients will benefit significantly from VNS therapy. Approximately 4 of 5 patients will retain VNS therapy, and in cases of cessation, this is most commonly related to minimal benefit. Underlying demographics, aetiology or seizure nature do not influence outcomes. This 20-year Queensland assessment of VNS therapy outcomes informs long-term expectation of VNS therapy.
Authors: C DeGiorgio; C Heck; S Bunch; J Britton; P Green; M Lancman; J Murphy; P Olejniczak; J Shih; S Arrambide; J Soss Journal: Neurology Date: 2005-07-26 Impact factor: 9.910
Authors: Robert E Elliott; Amr Morsi; Eric B Geller; Chad C Carlson; Orrin Devinsky; Werner K Doyle Journal: Neurosurgery Date: 2011-12 Impact factor: 4.654
Authors: L Galbarriatu; I Pomposo; J Aurrecoechea; A Marinas; M Agúndez; J C Gómez; M A Acera; M J Martínez; E Valle; I Maestro; B Mateos; A Cabrera; J Fernández; F Iturri; I Garamendi Journal: Clin Neurol Neurosurg Date: 2015-07-02 Impact factor: 1.876
Authors: Robert E Elliott; Shaun D Rodgers; Luigi Bassani; Amr Morsi; Eric B Geller; Chad Carlson; Orrin Devinsky; Werner K Doyle Journal: J Neurosurg Pediatr Date: 2011-05 Impact factor: 2.375
Authors: E Ben-Menachem; R Mañon-Espaillat; R Ristanovic; B J Wilder; H Stefan; W Mirza; W B Tarver; J F Wernicke Journal: Epilepsia Date: 1994 May-Jun Impact factor: 5.864